Silence Therapeutics has named Jeffrey Vick as its new CEO.
The company said it appointed Vick to “strengthen its core management team as [it] seeks to expand its business partnerships.” Silence has not had a CEO since it began refocusing on RNAi therapeutics in 2004 (see RNAi News, 7/29/2005).
Vick previously served in senior management at DepoTech, was vice president of corporate development for Cytoyia, vice president of business development at Genset, and vice president of corporate development and intellectual property at Centelion.
He holds a BS in chemistry from the University of Virginia, and an MS in chemistry from the University of California, San Diego. He also holds an MBA from Stanford Graduate School of Business.